Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, expectations were $-1.27. Operator: Welcome everyone to the Fourth Quarter and Year ...

Additionally, Unity Biotechnology also announced 3 Yehia Hashad, MD, executive vice president of research and development and ...

ExoPTEN, which is advancing towards first-in-human trials. The study demonstrated that ExoPTEN significantly enhances motor function recovery and improves blood flow at spinal cord injury sites, ...